Company intelligence / Profile preview

Aferetica

Mirandola, Emilia-Romagna, Italy

Ownership: Private
Development stage: Other

Overview

Aferetica’s PerLife System has demonstrated utility in reconditioning donor organs before transplantation, which improves viability and reduces graft failure/organ rejection; its technology is also used to support blood purification in critical care, offering improved patient outcomes in sepsis and inflammatory conditions

Therapeutic areas: Immunology
Modalities: DeviceBiologic (extracorporeal blood purification)
Industry: Therapeutic Medical Devices

Partnerships

CytoSorbents Corporation (Co-development of PerLife System and sorbent cartridges)

Beyond the preview

Go deeper on Aferetica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aferetica.

Explore the full profile